This should help the FPH SP: "The trial showed statistically...

This should help the FPH SP:
"The trial showed statistically significant results, with the primary outcome being a significant
reduction in patients’ exacerbation rate, or worsening of their condition (from 4.95 to 3.12 per
patient per year, p <0.001) for those being treated with nasal high flow therapy.
The study also showed for those patients using the myAirvo, that all cause hospitalisation
rates decreased from a rate of 1.39 to 0.79 per patient, over the course of the year, for those
who followed the protocol. Other positive results included the treatment group (myAirvo)
being better than the control group (standard care) in several quality of life assessments,
less breathlessness, better mobility and lower carbon dioxide retention levels for these
chronic patients."